['hypercholesterolemia']
['bempedoic acid 180mg', 'evolocumab']

        Inclusion Criteria:

          -  Age ≥18 years or legal age of majority depending on regional law

          -  Fasting, calculated LDL-C at screening ≥160 mg/dL and following PCSK9i therapy ≥70
             mg/dL

          -  Men and nonpregnant, nonlactating women

        Exclusion Criteria:

          -  Heterozygous (HeFH) or Homozygous (HoFH) Familial Hypercholesterolemia

          -  Total fasting TG ≥500 mg/dL

          -  Renal dysfunction or a glomerulonephropathy; eGFR <30 mL/min/1.73 m2

          -  Known cardiovascular disease (CVD), peripheral arterial disease (PAD), or
             cerebrovascular disease (CD)

          -  History of type 1 or type 2 diabetes

          -  Uncontrolled hypertension

          -  Uncontrolled hypothyroidism

          -  Liver disease or dysfunction

          -  Gastrointestinal conditions or procedures (including Lap-Band® or gastric bypass)

          -  History of hematologic or coagulation disorders

          -  History of malignancy (except non-metastatic basal or squamous cell carcinoma of the
             skin and cervical carcinoma in situ)

          -  Unexplained creatine kinase (CK) >3 × ULN

          -  Use of a cholesterylester transfer protein (CETP) inhibitor in the last 12 months
             prior to screening, such as: anacetrapib, dalcetrapib, or evacetrapib

          -  Pregnant or breast feeding, or planning to become pregnant during treatment and/ or
             within 30 days after the end of treatment
      